Annex № 4
To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from 09.11.2021
And Regulation (EU) 596/2014 of the European Parliament and of the Council

of 16 April 2014

INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED DURING THE SECOND QUARTER OF 2023 OF "SOPHARMA" AD

- 1.1. No change in the persons controlling the Company.
- 1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.3. No conclusion or execution of significant transactions.
- 1.4. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.5. Change of the auditors of the company No change of auditors. At the Regular General Meeting of Shareholders of "SOPHARMA" AD, held on 2 June 2023, the auditing company "BAKER TILLY KLITOU AND PARTNERS" OOD, based in Sofia, Acad. "Ivan Evst. Geshov" 104, for a registered auditor for inspection and certification of the Annual Financial Statements of the Company.
- 1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.
- 1.7. No purchases, sales or established pledges of shares in commercial companies by the issuer or its subsidiary.
- 1.8. The Company's management believes that the invasion of the Russian army in Ukraine could seriously affect its activity, since about 40% of the sales of production are realized in Ukraine and Russia

The company owns investments in two subsidiaries in Ukraine. As of December 31, 2021 the amount of the investment in the subsidiary Sopharma Ukraine is BGN 9,669 thousand and the amount of the investment in the subsidiary Vitamini is BGN 1,283 thousand. As of the date of approval of these separate financial statements the assets of these subsidiaries companies are not physically affected by military activities, but it may be necessary in the future to reconsider the value of these investments depending on the development of the war and its impact on the activities of companies.

"Sopharma" AD informs all interested parties that the individual financial statements of the Company as at 30 June 2023 have not been verified by a registered auditor.